Optos has announced the launch of an artificial intelligence (AI) solution that automated the detection of diabetic retinopathy (DR) and diabetic macular oedema using Optomap imaging.
Robert Kennedy, Optos CEO, said: ‘Through many clinical studies, we have established that the early assessment of DR using ultra-widefield imaging is very important for the management of a patient’s visual health. The addition of this automated solution will further help our customers to transform the way their patients are diagnosed and managed.’
The machine learning-based system was co-developed by Optos, Nikon, Verily Life Sciences and Google to provide rapid, automated screening.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
